Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

High body mass index patients have lower stages of esophageal carcinoma at diagnosis

Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis, reports the latest issue of the Diseases of the Esophagus.

News image

High body mass index is common in US adults.

In a small cohort of esophageal cancer patients treated with surgery, high-BMI and diagnosis of early stage esophageal cancer appeared associated.

Dr Jaffer Ajani and colleagues from Texas, USA evaluated a much larger cohort of esophageal cancer patients.

From a prospectively maintained database, the team analyzed 925 esophageal cancer patients who had surgery with or without adjunctive therapy.

Various statistical methods were used.

High-BMI patients do not experience higher rate of surgical complications
Diseases of the Esophagus

Among 925 patients, 69% had high-BMI, and 31% had normal body mass index.

High-BMI was associated with men, Caucasians, lower esophageal localization, adenocarcinoma histology, low baseline cT-stage, low baseline overall clinical stage, coronary artery disease, and diabetes.

The researchers found that normal-BMI was associated with weight loss, alcohol abuse, ever/current smoking, and baseline cN+.

High-BMI patients with cT1 tumors had significantly higher rates of gastresophageal reflux disease symptoms, gastresophageal reflux disease history, and Barrett's esophagus history compared with H-BMI patients with cT2 tumors.

The team noted that the median survival of normal-BMI patients was 37 months compared with 53 months for high-BMI patients.

The researchers found that older age, squamous histology, smoking, weight loss, high baseline stage, high number of ypN+, high surgical stage, and American Society of Anesthesia scores, 3 out of 4 were independent prognosticators for poor overall survival.

The researchers were able to perform propensity-based analysis of surgical complications between high-BMI and normal-BMI patients.

A comparison of fully matched 376 patients found no significant differences in the rate of complications between the 2 groups.

The team confirmed that a fraction of high-BMI patients with antecedent history is diagnosed with early baseline esophageal cancer.

Dr Ajani's team concludes, "Upon validation of our data in an independent cohort, refinements in surveillance of symptomatic high-BMI patients are warranted and could be implemented."

"Our data also suggest that high-BMI patients do not experience higher rate of surgical complications compared with normal-BMI patients."

Dis Esoph 2012: 25(7): 614622
24 October 2012

Go to top of page Email this page Email this page to a colleague

 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP
 28 July 2016 
HCV eradication in cirrhotic patients
 27 July 2016 
Bleeding GI recurrence with aspirin use
 27 July 2016 
IBD during pregnancy
 27 July 2016 
Gluten exposure in patients with celiac disease
 26 July 2016 
Post-infectious IBS after C. diff
 26 July 2016 
Gut microbiota and IBD
 26 July 2016 
Neighborhood variation in the use of laparoscopy for colon cancer
 25 July 2016 
Antibiotic prophylaxis for open colectomies
 25 July 2016 
Steroids in eosinophilic esophagitis
 25 July 2016 
Prevention of post-ERCP pancreatitis
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Fecal calprotectin and IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Screening diabetic patients for NAFLD
 19 July 2016 
Longterm clinical follow-up of living liver donors
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver cancer prediction scores in Hep B
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 12 July 2016 
Treatment of pediatric acute liver failure
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Factors that influence access to liver transplant
 11 July 2016 
Disturbed sleep and IBS
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Statins and cirrhosis in Hep B
 08 July 2016 
Genetic risk score and body mass index
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 05 July 2016 
Exercise and gastroesophageal reflux
 05 July 2016 
Colorectal surgery and dialysis
 04 July 2016 
Guidelines on PPI and NSAID prescription
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 01 July 2016 
Aspirin and colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us